Leukotriene Reduction


Excess production of leukotrienes promotes the inappropriate response to harmless antigenic substances that characterizes allergy. Leukotrienes are:

  • fatty acid-derived inflammatory mediators that play a significant role in the pathophysiology of allergic diseases, including asthma and allergic rhinitis
  • derived from the fatty acid arachidonic acid (AA), which is concentrated in the membrane phospholipids of blood cells
  • synthesized by circulating immune cells in response to a stimulus such as allergen exposure

In a placebo-controlled clinical study involving 43 adult patients with mild to moderate atopic asthma, Efficas Care significantly decreased leukotriene production within 28 days.

The clinical study demonstrated that leukotriene production was significantly decreased compared to placebo in patients with mild to moderate atopic asthma and was well tolerated in this population (18). Preliminary evidence of quality of life (QOL) improvements was also obtained (44)

Study Design

A single-center, randomized, double-blind, placebo controlled, parallel-group prospective efficacy clinical trial in patients with mild to moderate asthma conducted at Wake Forest University School of Medicine. Patient population consisted of 43 adult patients age 15 to 65 years. All patients had a diagnosis of asthma for at least one year and controlled their symptoms with beta-agonists and/or theophylline only. They also had a positive result on the methacholine challenge test as indicated by a PC20 of <8mg/ml, and a FEV1 > 70% of the predicted value. No patient could have taken inhaled or systemic steroids for = 4 weeks before study enrollment.

1. Surette, M.E. et al., 2003b. Inhibition of Leukotriene Synthesis by a Novel Dietary Fatty Acid Formulation in patients with Atopic asthma: A randomized, placebo-controlled, parallel-group, prospective trial. Clinical Therapeutics 25(3):972-979